The resulting 124 I-evuzamitide (previously known as AT-01) has been shown to detect amyloidosis in organs like the heart, ...
Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/ ...
About NEXICART-2 NEXICART-2 (NCT06097832) is an ongoing multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational ...
A hidden atrial dysfunction may raise stroke risk in people with transthyretin amyloid cardiomyopathy (ATTR-CM); however, a ...
BridgeBio Pharma, Inc. (Nasdaq: BBIO) ('BridgeBio” or the 'Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will be ...
A hidden atrial dysfunction may raise stroke risk in people with transthyretin amyloid cardiomyopathy (ATTR-CM); however, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback